Intraoperative findings of stapes surgery in 34 ears from 22 patients with genetically confirmed osteogenesis imperfecta (OI) are reported, as well as the audiometric results after the longest postoperative follow-up published to date. Twenty-nine out of 34 ears underwent primary stapes surgery and 5 ears revision surgery. Postoperative audiometric follow-up ranged from 6 months to 37 years. Stapes footplates were fixed in all ears. Additionally, footplates were thickened or fragile, stapes crura atrophic or fractured, and middle ear mucosae thickened or hypervascularized. Short-term postoperative audiometry revealed improved hearing and reduced air-bone gaps in 28/29 primary operated ears and in all revision cases. In the 22 ears with long-term postoperative follow-up (mean duration: 16 years), hearing gain was still significant at the latest audiometric evaluation. Independently of the patients being diagnosed with OI type I or IV and independently of the underlying OI genotype, beneficial results are obtained in the majority of OI patients undergoing primary or revision stapes surgery for reduction of conductive hearing loss components caused by stapes footplate fixation. Despite the progressive course of the concomitant sensorineural component, hearing gain remains beneficial over several decades.

Keywords:
Osteogenesis imperfecta, Hearing loss, Stapes surgery
1.
Albahnasawy L, Kishore A, O’Reilly BF: Results of stapes surgery on patients with osteogenesis imperfecta. Clin Otolaryngol Allied Sci 2001;26:473–476.
2.
Altmann F, Kornfeld M: Osteogenesis imperfecta and otosclerosis: new investigations. Ann Otol Rhinol Laryngol 1967;76:89–104.
3.
Armstrong BW: Stapes surgery in patients with osteogenesis imperfecta. Ann Otol Rhinol Laryngol 1984;93:634–635.
4.
Basel D, Steiner RD: Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet Med 2009;11:375–385.
5.
Bretlau P, Jorgensen MB: Otosclerosis and osteogenesis imperfecta. Arch Otolaryngol 1969;90:4–10.
6.
Brosnan M, Burns H, Jahn AF, Hawke M: Surgery and histopathology of the stapes in osteogenesis imperfecta tarda. Arch Otolaryngol 1977;103:294–298.
7.
Byers PH, Wallis GA, Willing MC: Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet 1991;28:433–442.
8.
Cremers C, Garretsen T: Stapes surgery in osteogenesis imperfecta. Am J Otol 1989;10:474–476.
9.
Dieler R, Muller J, Helms J: Stapes surgery in osteogenesis imperfecta patients. Eur Arch Otorhinolaryngol 1997;254:120–127.
10.
Ferekidis E, Stavroulaki P, Vossinakis I, Yiotakis J, Manolopoulos L, Adamopoulos G: Stapedotomy in osteogenesis imperfecta patients. J Laryngol Otol 2000;114:424–428.
11.
Garretsen TJ, Cremers CW: Ear surgery in osteogenesis imperfecta. Clinical findings and short-term and long-term results. Arch Otolaryngol Head Neck Surg 1990;116:317–323.
12.
Garretsen TJ, Cremers CW: Clinical and genetic aspects in autosomal dominant inherited osteogenesis imperfecta type I. Ann NY Acad Sci 1991a;630:240–248.
13.
Garretsen TJ, Cremers CW: Stapes surgery in osteogenesis imperfecta: analysis of postoperative hearing loss. Ann Otol Rhinol Laryngol 1991b;100:120–130.
14.
Garretsen AJ, Cremers CW, Huygen PL: Hearing loss (in nonoperated ears) in relation to age in osteogenesis imperfecta type I. Ann Otol Rhinol Laryngol 1997;106:575–582.
15.
Hall IS, Ogilvie RF: Otosclerosis in osteogenesis imperfecta. A study in the etiology of otosclerosis. Acta Otolaryngol 1961;53:202–206.
16.
Hartikka H, Kuurila K, Korkko J, Kaitila I, Grenman R, Pynnonen S, Hyland J C, la-Kokko L: Lack of correlation between the type of COL1A1 or COL1A2 mutation and hearing loss in osteogenesis imperfecta patients. Hum Mutat 2004;24:147–154.
17.
Holdsworth CE, Endahl GL, Soifer N, Richardson KE, Eyring EJ: Comparative biochemical study of otosclerosis and osteogenesis imperfecta. Arch Otolaryngol 1973;98:336–339.
18.
Kosoy J, Maddox HE: Surgical findings in van der Hoeve’s syndrome. Arch Otolaryngol 1971;93:115–122.
19.
Kuurila K, Kaitila I, Johansson R, Grenman R: Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann Otol Rhinol Laryngol 2002;111:939–946.
20.
Kuurila K, Pynnonen S, Grenman R: Stapes surgery in osteogenesis imperfecta in Finland. Ann Otol Rhinol Laryngol 2004;113:187–193.
21.
Monsell EM, Balkany T, Gates G, Goldenberg R, Meyerhoff W, House J: Committee on Hearing and Equilibrium guidelines for the evaluation of results of treatment of conductive hearing loss. Otolaryngol Head Neck Surg 1995;113:186–187.
22.
Patterson CN, Stone HB: Stapedectomy in van der Hoeve’s syndrome. Laryngoscope 1970;80:544–558.
23.
Pedersen U: Hearing loss in patients with osteogenesis imperfecta. A clinical and audiological study of 201 patients. Scand Audiol 1984;13:67–74.
24.
Pedersen U: Osteogenesis imperfecta clinical features, hearing loss and stapedectomy. Biochemical, osteodensitometric, corneometric and histological aspects in comparison with otosclerosis. Acta Otolaryngol Suppl 1985;415:1–36.
25.
Shea JJ, Postma DS: Findings and long-term surgical results in the hearing loss of osteogenesis imperfecta. Arch Otolaryngol 1982;108:467–470.
26.
Sillence DO, Senn A, Danks DM: Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16:101–116.
27.
Stewart EJ, O’Reilly BF: A clinical and audiological investigation of osteogenesis imperfecta. Clin Otolaryngol Allied Sci 1989;14:509–514.
28.
Swinnen FK, De Leenheer EM, Coucke PJ, Cremers CW, Dhooge IJ: Audiometric, surgical, and genetic findings in 15 ears of patients with osteogenesis imperfecta. Laryngoscope 2009;119:1171–1179.
29.
Van der Rijt AJ, Cremers CW: Stapes surgery in osteogenesis imperfecta: results of a new series. Otol Neurotol 2003;24:717–722.
30.
Vincent R, Gratacap B, Oates J, Sperling NM: Stapedotomy in osteogenesis imperfecta: a prospective study of 23 consecutive cases. Otol Neurotol 2005;26:859–865.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.